2-Imidazol-1-yl-1-(2-phenylphenyl)ethanone | 73932-08-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Imidazol-1-yl-1-(2-phenylphenyl)ethanone
• CAS: 73932-08-8
• 化学式: C₁₇H₁₄N₂O
• 分子量: 262.311
• InChiKey: TVYSNMRTGOTTCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Imidazol-1-yl-1-(2-phenylphenyl)ethanone 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以70%的产率得到2-Imidazol-1-yl-1-(2-phenylphenyl)ethanol
  参考文献：
  名称：

  Synthesis and anticonvulsant activity of N-(benzoylalkyl)imidazoles and N-(.omega.-phenyl-.omega.-hydroxyalkyl)imidazoles

  摘要：

  A novel series of N-(benzoylalkyl)imidazoles and N-(omega-phenyl-omega-hydroxyalkyl)imidazoles was synthesized and evaluated for anticonvulsant activity in mice against maximal electroshock induced seizures. Some of the compounds showed an activity comparable to or better than phenytoin and phenobarbital. The N-[beta-[4-(beta-phenylethyl)phenyl]-beta-hydroxyethyl]imidazole (38) was selected for further studies; preclinical toxicology and additional efficacy evaluations are in progress. Structure-activity relationships are discussed.

  DOI：

  10.1021/jm00138a017
• 作为产物：
  描述：

  1-(2-联苯基)乙酮 在 溴 作用下， 以 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 2-Imidazol-1-yl-1-(2-phenylphenyl)ethanone
  参考文献：
  名称：

  Synthesis and anticonvulsant activity of N-(benzoylalkyl)imidazoles and N-(.omega.-phenyl-.omega.-hydroxyalkyl)imidazoles

  摘要：

  A novel series of N-(benzoylalkyl)imidazoles and N-(omega-phenyl-omega-hydroxyalkyl)imidazoles was synthesized and evaluated for anticonvulsant activity in mice against maximal electroshock induced seizures. Some of the compounds showed an activity comparable to or better than phenytoin and phenobarbital. The N-[beta-[4-(beta-phenylethyl)phenyl]-beta-hydroxyethyl]imidazole (38) was selected for further studies; preclinical toxicology and additional efficacy evaluations are in progress. Structure-activity relationships are discussed.

  DOI：

  10.1021/jm00138a017

文献信息

• Hydroxyethyl-azole, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
  申请人：BAYER AG

  公开号：EP0011769A1

  公开（公告）日：1980-06-11

  Hydroxyethyl-azole der allgemeinen Formel in welcher Az für Imidazol oder Triazol steht, R für gegebenenfalls substituiertes Phenly, Naphthyl oder Tetrahydronaphthyl steht, R1 für gegebenenfalls substituiertes Phenyl oder Cycloalkyl steht und R2 für Wasserstoff steht oder R' und R2 gemeinsam in o-Stellung zueinander für eine gegebenenfalls substituierte, mehrgliedrige Methylenbrücke oder zusammen mit dem Phenylring für Naphthyl stehen, R3 für Halogen, Alkyl, Alkoxy oder Halogenalkyl steht und n für 0, 1, 2 oder 3 steht, weisen antimykotische Eigenschaften auf.

  通式如下的羟乙基唑 其中 Az 是咪唑或三唑、 R 是任选取代的苯基、萘基或四氢萘基、 R1 代表任选取代的苯基或环烷基，以及 R2 是氢或 R' 和 R2 在彼此相对的 o 位上代表任选取代的多元亚甲基桥，或与苯基环一起代表萘基、 R3 代表卤素、烷基、烷氧基或卤代烷基，以及 n 为 0、1、2 或 3、 具有抗真菌特性。
• Hydroxypropyl-imidazole, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
  申请人：BAYER AG

  公开号：EP0005250B1

  公开（公告）日：1981-08-12
• NARDI, D.;TAJANA, A.;LEONARDI, A.;PENNINI, R.;PORTIOLI, F.;MAGISTRETTI, M+, J. MED. CHEM., 1981, 24, N 6, 727-731
  作者：NARDI, D.、TAJANA, A.、LEONARDI, A.、PENNINI, R.、PORTIOLI, F.、MAGISTRETTI, M+

  DOI：——

  日期：——
• US4246274A
  申请人：——

  公开号：US4246274A

  公开（公告）日：1981-01-20
• Synthesis and anticonvulsant activity of N-(benzoylalkyl)imidazoles and N-(.omega.-phenyl-.omega.-hydroxyalkyl)imidazoles
  作者：Dante Nardi、Alberto Tajana、Amedeo Leonardi、Renzo Pennini、Ferruccio Portioli、Maria Jose Magistretti、Alessandro Subissi

  DOI：10.1021/jm00138a017

  日期：1981.6

  A novel series of N-(benzoylalkyl)imidazoles and N-(omega-phenyl-omega-hydroxyalkyl)imidazoles was synthesized and evaluated for anticonvulsant activity in mice against maximal electroshock induced seizures. Some of the compounds showed an activity comparable to or better than phenytoin and phenobarbital. The N-[beta-[4-(beta-phenylethyl)phenyl]-beta-hydroxyethyl]imidazole (38) was selected for further studies; preclinical toxicology and additional efficacy evaluations are in progress. Structure-activity relationships are discussed.